For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) to establish the Health Economics Methods Advisory (HEMA), a new ...

This topic was evaluated as a single technology evaluation by the highly specialised technologies evaluation committee, which is a standing advisory committee of NICE. Committee members are asked to ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered as a cost comparison evaluation by the lead team of the highly specialised technologies ...

Olaparib (Lynparza, AstraZeneca) is indicated as 'monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2 negative locally advanced or metastatic breast cancer.

Olaparib is recommended, within its marketing authorisation, as an option for treating HER2-negative locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults who ...

There is a commercial access agreement for olaparib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...

A resource impact template has not been produced for this appraisal. The resource impact template for selpercatinib for advanced thyroid cancer with RET alterations untreated with a targeted cancer ...

Ganaxolone (Ztalmy, Orion and Marinus) is indicated for the 'adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 ...